Leukemia in 2020 and Beyond

CML — First-Line TKI Landscape and Relapsed/Refractory and New Targets. ALL — Role of Monoclonal Antibodies and Bispecific Engagers, and the Role of CAR T Cells.

September 14 & 15, 2020

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, US

Faculty Members

Aaron Logan, MD, PhD
UCSF Health, San Francisco, CA, USA

Amir Fathi, MD
Massachusetts General Hospital, Boston, MA, USA

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Javier Pinilla, MD, PhD
Moffitt Cancer Center, Tampa, FL, USA

Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York City, NY, USA

Jerald Radich, MD
Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Naval Daver, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL, USA

Richard Stone, MD
Dana-Farber Cancer Institute, Boston, MA, USA

Agenda

Export meeting topics

View Agenda

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • CML: First-Line TKI Landscape
  • CML: Relapsed/Refractory and New Targets
  • ALL: Genetic Subsets
  • ALL: Role of Monoclonal Antibodies and Bispecific Engagers
  • ALL: Role of CAR T Cells
  • MDS: Low-Risk Disease
  • MDS: High-Risk Disease
  • AML: Patient Subsets
  • AML: Targeting FLT3 and BCL-2
  • AML: New Therapeutic Targets

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.